Chae and Hann Lai CL, Shouval D, Lok AS, et al. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New Engl J Med, 354:1011–20. Lampertico P, Marzano A, Levrero M, et al. 2006. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2 year analysis of 650 patients. J Hepatol, 44:S51. Lau GK, Cooksley H, Ribiero RM, et al. 2004. Randomized double blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg negative chronic hepatitis B: efﬁcacy and mechanism of treatment response. Hepato- logy, 40:1155A. Lau GK, Piratvisuth YT, Luo KX, et al. 2005. Peginterferon α-2a, lamivu- dine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 352:2682–95. Lee HJ, Suh JI, Jang BI. 1997. The therapeutic effect of recombinant interferon α in chronic hepatitis B patients. Korean J of Gastroenterol, 29:777–85. Lee WM. 1997. Medical progress: hepatitis B virus infection. N Engl J Med, 337:1733–45. Lee YS, Suh DJ, Lim YS, et al. 2006. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 43:1385–91. Leung N, Peng CY, Sollano J, et al. 2006. Entecavir results in higher HBV DNA reduction VS adefovir in chronically infected HBeAg(+) antiviral-naïve adults: 24 week results (E.A.R.L.Y. Study). Hepatology, 44(Suppl 1):554A. Liaw YF, Leung N, Guan R, et al. 2003. Asian-Paciﬁc consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol hepatol, 18:239–45. Liaw YF, Leung N, Guan R, et al. 2005. Asian-Paciﬁc consensus state- ment on the management of chronic hepatitis B: a 2005 update. Liver international, 25:472–89. Liaw YF, Leung NW, Chang TT, et al. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asian Hepatitis Lamivudine Study Group. Gastroenterology, 119:172–80. Liaw YF, Sung JJ, Chow WC, et al. 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351:1521–31. Lin CC, Wu JC, Chang TT, et al. 2001. Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen- negative chronic hepatitis B in Taiwan. J Viral Hepatitis, 8:438–46. Lok AS, Lai CL, Leung N, et al. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 125:1714–22. Lok AS, Lai CL, Wu PC, et al. 1988. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet, 332:298–302. Lok ASF, McMahon BJ. 2001. AASLD Practice guidelines: chronic hepatitis B. Hepatology, 34:1225–41. Lok ASF, McMahon BJ. 2004. AASLD practice guidelines:chronic hepatitis B: update of recommendation. Hepatology, 39:857–61. Marcellin P, Chang T, Lim S, et al. 2005. Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HbeAg-positive chronic hepatitis B patients. J Hepatol, 42(Suppl 2):31. Marcellin P, Chang T-T, Lim SG, et al. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 348:808–16. Marcellin P, Lau GKK, Bonino F, et al. 2004. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg- negative chronic hepatitis B. N Engl J Med, 351:1206–17. Martin P, Hann HW, Westerberg S, et al. 1998. Interferon-alpha2b therapy is efﬁcacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trial. Dig Dis Sci, 43:875–9. Nowak MA, Bonhoeffer S, Hill AM, et al. 1996. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci, 93:4398–402. Nunez M, Perez-Olimeda M, Diaz B, et al. 2002, Activity of tenofovir on hepatitis B virus replicaion in HIV–co-infected patients failing or partially responding to lamivudine. AIDS, 16:2352–4. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. 2005. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology, 42:121–9. Perrillo RP. 2006. Therapy of hepatitis B-viral suppression or eradication? Hepatology, 43 (Suppl 1):S183–93. Perrillo RP, Lai CL, Liaw YF, et al. 2002. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology, 36:186–94. Perrillo RP, Schiff ER, Davis GL, et al. 1990. A randomized, controlled trial of interferon α-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. The hepatitis interventional therapy group. New Engl J Med, 323:295–301. Prati D, Taiolo E, Zanella A, et al. 2002. Updated deﬁnitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med, 137:1–10. Ristig MB, Crippin J, Aberg JA, et al. 2002. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeﬁciency virus/ hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis, 186:1844–7. Rosmawati M, Lai CL, Lao L, et al. 2003. Baseline ALT level does not predict viral load reduction in response to entecavir therapy. J of Hepatol 38:166, Abstr 574. Ryu SH, Chung YH, Choi MH, et al. 2003. Long term additional lamivu- dine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol, 39:614–19. Snow A, Thibault V, Qi X, et al. 2005. Combination of adefovir (ADV) and lamivudine (LVD) prevented emergence of adefovir resistance muta- tions in chronic hepatitis B patients with lamivudine-resistant HBV. Gastroenterology, 128:A745. Sung JJY, Lai YF, Zeuzem S, et al. 2003. A randomized, double-blind phase II study of lamivudine (LVD) compared o lamivudine plus adefovir dipivoxil (ADV) for treatment if naïve patients with chronic hepatitis B (CHB) week 52 analysis. J Hepatol, 38 (Suppl 2):25. The EASL Jury. 2003. EASL international consensus conference on hepatitis B. J Hepatol, 38:533–40. Van Bommel F, Wunsche T, Mauss S, et al. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus infection. Hepatology, 40:1421–5. Van Bommel F, Wensche T, Schurmann D, et al. 2003. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection. Hepatology 38(Suppl 1):A246. Yuen MF, Sabion E, Hui CK, et al. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology, 34:785–91. Zeuzem S, de Man RA, Honkoop P et al. 1997. Dynamics of hepatitis B virus infection in vivo. J of Hepatol, 27:431–6. 612 Therapeutics and Clinical Risk Management 2007:3(4)